Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | NRP1 | O14786 | 2/20 | 0.39 |
| ▸ | GLP1R | P43220 | 7/20 | 0.39 |
| ▸ | GIPR | P48546 | 7/20 | 0.39 |
| ▸ | GCGR | P47871 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31197908 | 0.98 | APLNR (0.44) | GRB2APLNRBDKRB2GLP1RGIPR | |
| SCHEMBL30744292 | 0.94 | APLNR (0.42) | GRB2APLNROPRD1OPRM1GLP1R | |
| SCHEMBL31197912 | 0.94 | GRB2 (0.44) | GRB2BDKRB2OPRD1OPRM1NRP1 | |
| SCHEMBL31337813 | 0.93 | GRB2 (0.44) | GRB2APLNRBDKRB2OPRD1OPRM1 | |
| SCHEMBL30744275 | 0.91 | BDKRB2 (0.39) | BDKRB2OPRD1OPRM1GLP1RGIPR | |
| SCHEMBL31197909 | 0.88 | GRB2 (0.45) | GRB2 | |
| SCHEMBL30543476 | 0.88 | GRB2 (0.44) | GRB2APLNRBDKRB2OPRD1OPRM1 | |
| SCHEMBL30422395 | 0.87 | GRB2 (0.44) | GRB2APLNR | |
| SCHEMBL38651991 | 0.86 | APLNR (0.43) | GRB2APLNRBDKRB2OPRD1OPRM1 | |
| SCHEMBL29468889 | 0.86 | GRB2 (0.42) | GRB2APLNRBDKRB2OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589158-B2 | GLP-1/GIP dual agonist, preparation method and use thereof | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2026-03-31 | — | — | US | disclosed |
| CN-119522233-A | GLP-1/GIP double agonist and preparation method and application thereof | 杭州中美华东制药有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20240325549-A1 | GLP-1/GIP DUAL AGONIST, PREPARATION METHOD AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2024012472-A1 | GLP-1/GIP DUAL AGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 杭州中美华东制药有限公司 | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12589158-B2 | GLP-1/GIP dual agonist, preparation method and use thereof | GLP1R, GIPR, IAPP | GRB2 761/4885APLNR 157/4885BDKRB2 1038/4885 |
| US-20240325549-A1 | GLP-1/GIP DUAL AGONIST, PREPARATION METHOD AND USE THEREOF | GLP1R, GIPR, GCGR | GRB2 509/4885APLNR 190/4885BDKRB2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.